Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | -0.27 | -0.64 | 0.51 |
| FCF Yield | -25.84% | -8.24% | -8.04% | -5.92% |
| EV / EBITDA | -3.91 | -7.30 | -9.24 | -13.09 |
| Quality | ||||
| ROIC | -284.73% | 203.60% | 607.15% | -107.77% |
| Gross Margin | -39.12% | -5.35% | 95.03% | 93.92% |
| Cash Conversion Ratio | – | 0.74 | 0.97 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.82% | 30.46% | 38.66% | 40.11% |
| Free Cash Flow Growth | -55.65% | -3.34% | -40.61% | -14.10% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | 0.17 | 0.08 | 1.07 |
| Interest Coverage | 0.00 | -26.04 | -94.54 | -1,186.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -55.11 | -192.17 | -1,587.33 | -867.38 |